Indeed, we have demonstrated that the WN1316 treatment augmented the level of ATF3 protein and GSH in human neuronal cells in vitro and down-regulated the level of IL-1β and iNOS in the lumbar spinal cord of ALS(SOD1H46R) mice. The gene discussed is ATF3; the disease is amyotrophic lateral sclerosis.